17.11.2014 - Pfizer is going to invest $ 850 million in new drug

American corporation Pfizer and German Merck KGaA, agreed to cooperate on the development of anti-tumor drug. As a result, Merck KGaA will receive $ 850 million for the development and preparation for sale anti-PD-L1, and can later get another $ 2 billion. The deal is the biggest in the pharmaceutical business. Given the ambitious plans of the two companies on a background of stable sales and earnings growth, we recommend to keep shares of these companies in the long term portfolio with the growth potential of up to 35% for the year.

RISK WARNING: Trading of complex financial products, such as Stocks, Futures, Foreign Exchange ("Forex"), Contracts for Difference ("CFDs"), Indices, Options, or other financial derivatives, on "margin" carries a high level of risk, and may not be suitable for all investors. The possibility exists that you could sustain a loss of some or all of your initial investment and, therefore, you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with trading these markets, and seek advice from an independent financial advisor if you have any questions or doubts. Please carefully read our full "Risk Disclosure" and "Risk Disclosures for Financial Instruments & Investment Services". FXFINPRO Capital is the trading name of PFX Financial Professionals Limited, a limited liability company formed under the laws of Cyprus, registered with the Registrar of Companies in Nicosia, Cyprus, under nr. HE 237840 and regulated by the Cyprus Securities and Exchange Commission with license number 193/13.